Skip to main content
Premium Trial:

Request an Annual Quote

Bruker, Affymetrix Shares Drop Sharply

Shares in Bruker BioSciences and Affymetrix each dropped more than 17 percent this past week after both firms released their first-quarter results.
 
Affymetrix failed to meet Wall Street expectations for profit and revenue, leading to a 17.4 percent decline for the five-day trading period ended Tuesday. Meanwhile, Bruker shares fell 17.8 percent, even though it posted first-quarter revenue growth of 16.5 percent. Bruker’s stock had surged throughout the first quarter, and while a sell-off is not uncommon following the release of quarterly results, the reasons for such a massive decline are not clear.
 
On the other end of the spectrum, shares in Sequenom gained 19 percent for the week after the firm announced it had placed $20 million of common stock with institutional investors.
 
Overall, the BCW Index dipped .2 percent, while the Dow Jones Industrial Average gained 1.4 percent, the Nasdaq was up .3 percent, and the Nasdaq Biotech Index was flat with last week.

 
 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price
(May 1, 2007)
Starting Price
(
April 24, 2007)
% change
Affymetrix
AFFX
25.9
31.34
-17.36
Agilent
A
35.99
35.34
1.84
Applied Biosystems
ABI
31.11
30.8
1.01
Beckman
BEC
63.32
62.06
2.03
Becton Dickinson
BDX
79.63
78.11
1.95
Bio-Rad
BIO
70.66
69.57
1.57
Bruker
BRKR
9.17
11.15
-17.76
Caliper
CALP
5.47
5.72
-4.37
Cepheid
CPHD
11.34
12.1
-6.28
Illumina
ILMN
32.69
32.77
-0.24
Invitrogen
IVGN
65.87
66.81
-1.41
Luminex
LMNX
13.75
14.21
-3.24
MDS
MDZ
19.25
18.88
1.96
Millipore
MIL
73.88
74.31
-0.58
PerkinElmer
PKI
24.31
24.79
-1.94
Qiagen
QGEN
17.68
17.69
-0.06
Sequenom
SQNM
3.56
2.99
19.06
Sigma-Aldrich
SIAL
42.29
41.51
1.88
Stratagene
STGN
10.78
10.73
0.47
Thermo
TMO
52.34
49.88
4.93
Third Wave
TWTI
5.32
5.74
-7.32
Waters
WAT
59.41
58.96
0.76
BCW Index Average  
34.26
34.34
-0.23
The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.